Significance of the interleukin-1 receptor antagonist/interleukin-1 beta ratio as a prognostic factor in patients with pulmonary sarcoidosis
- PMID: 10940792
- DOI: 10.1159/000029536
Significance of the interleukin-1 receptor antagonist/interleukin-1 beta ratio as a prognostic factor in patients with pulmonary sarcoidosis
Abstract
Background: Various factors such as serum angiotensin-converting enzyme (sACE) activity, bronchoalveolar lavage (BAL) fluid lymphocyte percent, CD4/CD8 ratio, and shadows on chest radiograph have been identified as indexes of disease activity in patients with sarcoidosis. However, it remains to be confirmed whether these factors can predict clinical outcomes.
Objective: To examine whether the interleukin-1 receptor antagonist (IL-1ra)/IL-1 beta ratio can predict the clinical course, we prospectively followed the clinical courses of 30 patients with pulmonary sarcoidosis 4 years after measurement of immunoreactive amounts of IL-1ra or IL-1 beta in the culture supernatants obtained from BAL fluid macrophages.
Methods: Immunoreactive amounts of IL-1ra or IL-1 beta were measured using ELISA. Changes in pulmonary function, sACE activity, and shadows on chest radiographs during observation periods were evaluated as markers of changes in disease activity.
Results: We found that the patients whose shadows on chest radiographs showed improvement had a higher molar IL-1ra/IL-1 beta ratio than the patients whose shadows persistently remained 4 years after BAL examination (p < 0.05). The molar ratio was found to be positively correlated with improvement of percent vital capacity (p < 0.05) and negatively correlated with the ratio of sACE activity at the time of the last observation to sACE activity at the time of BAL (sACE(LAST)/sACE(BAL), p < 0.01). The sACE(LAST)/sACE(BAL) ratio was significantly lower in patients whose shadows on chest radiographs decreased than in those whose shadows remained unchanged (p < 0.005).
Conclusion: The IL-1ra/IL-1 beta ratio in the BAL fluid macrophage culture supernatants in patients with pulmonary sarcoidosis could be a useful marker in predicting the persistence of granulomatous lesions (chronicity).
Copyright 2000 S. Karger AG, Basel
Similar articles
-
Quantitative evaluation of the IL-1 beta and IL-1 receptor antagonist obtained from BALF macrophages in patients with interstitial lung diseases.Sarcoidosis Vasc Diffuse Lung Dis. 1997 Mar;14(1):39-45. Sarcoidosis Vasc Diffuse Lung Dis. 1997. PMID: 9186988
-
Correlative analysis of longitudinal changes in bronchoalveolar lavage, 67gallium scanning, serum angiotensin-converting enzyme activity, chest X-ray, and pulmonary function tests in pulmonary sarcoidosis.Jpn J Med. 1987 Aug;26(3):360-7. doi: 10.2169/internalmedicine1962.26.360. Jpn J Med. 1987. PMID: 2826860
-
Imbalances between tumor necrosis factor-alpha and its soluble receptor forms, and interleukin-1beta and interleukin-1 receptor antagonist in BAL fluid of cavitary pulmonary tuberculosis.Chest. 2000 Jan;117(1):103-9. doi: 10.1378/chest.117.1.103. Chest. 2000. PMID: 10631206
-
Elevated serum levels of lysozyme in desquamative interstitial pneumonia.Intern Med. 2010;49(9):847-51. doi: 10.2169/internalmedicine.49.3193. Epub 2010 Apr 30. Intern Med. 2010. PMID: 20453406 Review.
-
Clinical courses and prognoses of pulmonary sarcoidosis.Curr Opin Pulm Med. 1999 Sep;5(5):293-8. doi: 10.1097/00063198-199909000-00005. Curr Opin Pulm Med. 1999. PMID: 10461533 Review.
Cited by
-
Transient expression of IL-1beta induces acute lung injury and chronic repair leading to pulmonary fibrosis.J Clin Invest. 2001 Jun;107(12):1529-36. doi: 10.1172/JCI12568. J Clin Invest. 2001. PMID: 11413160 Free PMC article.
-
HIF-1α regulates IL-1β and IL-17 in sarcoidosis.Elife. 2019 May 1;8:e44519. doi: 10.7554/eLife.44519. Elife. 2019. PMID: 30946009 Free PMC article.
-
The Immunogenetics of Granulomatous Diseases.Adv Exp Med Biol. 2022;1367:349-368. doi: 10.1007/978-3-030-92616-8_13. Adv Exp Med Biol. 2022. PMID: 35286702
-
Genetics of sarcoidosis: candidate genes and genome scans.Proc Am Thorac Soc. 2007 Jan;4(1):108-16. doi: 10.1513/pats.200607-141JG. Proc Am Thorac Soc. 2007. PMID: 17202299 Free PMC article. Review.
-
Emerging Molecular Targets for the Treatment of Refractory Sarcoidosis.Front Med (Lausanne). 2020 Nov 24;7:594133. doi: 10.3389/fmed.2020.594133. eCollection 2020. Front Med (Lausanne). 2020. PMID: 33330556 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
